Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.5010
-0.0188 (-3.62%)
At close: Jul 8, 2026, 4:00 PM EDT
0.5002
-0.0008 (-0.16%)
After-hours: Jul 8, 2026, 5:58 PM EDT
Pasithea Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
PAZ004, a macrocyclic MEK inhibitor, is advancing through clinical trials for NF1 and advanced cancers, showing a differentiated safety and PK profile with promising early efficacy. The program targets significant unmet needs, especially in cutaneous neurofibroma, and is supported by strong patent protection and recent financing.